Abstract bekijken

Deze abstract is toegekend aan sessie AOB Poster session 1 - Glaucoma – Posterior segment/Retinal disease
TitelIntravitreal injected fluid dispersion: importance of injection technique.
Abstract Nr.1025
DoelTo evaluate the dispersion of intravitreal injected solutions and to investigate the influence of varying injection techniques.
MethodesProspective experimental study using enucleated porcine eyes and ultra-high resolution computed tomography (UHRCT) scanning to visualize iomeprol intravitreal dispersion. 60 porcine eyes were divided over 12 different groups according to the injection procedure: fast (2 sec) or slow (10 sec) injection speed and needle tip location (6 and 12 mm needle shaft insertion or premacular needle tip placement verified by indirect ophthalmoscopy). For each of these combinations eyes were either injected the combination of V20I (which is an analogue of ocriplasmin) and iomeprol or iomeprol alone. Distance to the macula and volume measurements were performed at 1, 2, 3 and 5 hours after injection.
ResultatenSixty fresh enucleated porcine eyes were injected with iomeprol or a combination of iomeprol and V20I. The measured contrast bolus volume increases slowly over time to an average of 0.70 (p=0.03), 1.04 (P=0.006) and 0.79 (p=0.0001) cm³ 5 hours after the injection for 6, 12mm and premacular intravitreal injections, respectively. The distance to the macular marker was significantly lower for premacular injections in respect to 6 mm needle shaft insertion depths.
ConclusieUHRCT with 3-D reconstruction offers the possibility to study the dispersion of intravitreal injected solutions in a non-invasive manner. Premacular intravitreal injections under indirect funduscopic guidance assured a targeted contrast delivery.
BelangenverstrengelingJa
Details verstrengelde belangenPeter Stalmans receives lecture fees from Alcon, DORC, Haag-Streit and Thrombogenics; is a consultant for Alcon, Bausch&Lomb, DORC, Nano-Retina, Zeiss and Vitreq; and receives grant support from Thrombogenics.
Auteur 1
NaamWILLEKENS
InitialenK
InstituutUZ Leuven
StadLeuven
Auteur 2
NaamReyns
InitialenG
InstituutThromboGenics NV
StadLeuven
Auteur 3
NaamDiricx
InitialenM
InstituutThromboGenics NV
StadLeuven
Auteur 4
NaamVanhove
InitialenM
InstituutThromboGenics NV
StadLeuven
Auteur 5
NaamNoppen
InitialenB
InstituutThromboGenics NV
StadLeuven
Auteur 6
NaamCoudyzer
InitialenW
InstituutUZ Leuven
StadLeuven
Auteur 7
NaamNi
InitialenY
InstituutUZ Leuven
StadLeuven
Auteur 8
NaamFeyen
InitialenJHM
InstituutThromboGenics NV
StadLeuven
Auteur 9
NaamStalmans
InitialenP
InstituutUZ Leuven
StadLeuven
top ^